000186587 001__ 186587
000186587 005__ 20240229154900.0
000186587 0247_ $$2doi$$a10.1007/s11060-022-04217-y
000186587 0247_ $$2pmid$$apmid:36598613
000186587 0247_ $$2ISSN$$a0167-594x
000186587 0247_ $$2ISSN$$a0167-594X
000186587 0247_ $$2ISSN$$a1573-7373
000186587 0247_ $$2altmetric$$aaltmetric:140840935
000186587 037__ $$aDKFZ-2023-00023
000186587 041__ $$aEnglish
000186587 082__ $$a610
000186587 1001_ $$00000-0003-0150-1328$$aEichkorn, Tanja$$b0
000186587 245__ $$aAnalysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.
000186587 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2023
000186587 3367_ $$2DRIVER$$aarticle
000186587 3367_ $$2DataCite$$aOutput Types/Journal article
000186587 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685538892_22950
000186587 3367_ $$2BibTeX$$aARTICLE
000186587 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186587 3367_ $$00$$2EndNote$$aJournal Article
000186587 500__ $$a2023 May;162(3):489-501
000186587 520__ $$aProton beam radiotherapy (PRT) has been demonstrated to improve neurocognitive sequelae particularly. Nevertheless, following PRT, increased rates of radiation-induced contrast enhancements (RICE) are feared. How safe and effective is PRT for IDH-mutated glioma WHO grade 2 and 3?We analyzed 194 patients diagnosed with IDH-mutated WHO grade 2 (n = 128) and WHO grade 3 (n = 66) glioma who were treated with PRT from 2010 to 2020. Serial clinical and imaging follow-up was performed for a median of 5.1 years.For WHO grade 2, 61% were astrocytoma and 39% oligodendroglioma while for WHO grade 3, 55% were astrocytoma and 45% oligodendroglioma. Median dose for IDH-mutated glioma was 54 Gy(RBE) [range 50.4-60 Gy(RBE)] for WHO grade 2 and 60 Gy(RBE) [range 54-60 Gy(RBE)] for WHO grade 3. Five year overall survival was 85% in patients with WHO grade 2 and 67% in patients with WHO grade 3 tumors. Overall RICE risk was 25%, being higher in patients with WHO grade 2 (29%) versus in patients with WHO grade 3 (17%, p = 0.13). RICE risk increased independent of tumor characteristics with older age (p = 0.017). Overall RICE was symptomatic in 31% of patients with corresponding CTCAE grades as follows: 80% grade 1, 7% grade 2, 13% grade 3, and 0% grade 3 + . Overall need for RICE-directed therapy was 35%.These data demonstrate the effectiveness of PRT for IDH-mutated glioma WHO grade 2 and 3. The RICE risk differs with WHO grading and is higher in older patients with IDH-mutated Glioma WHO grade 2 and 3.
000186587 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000186587 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186587 650_7 $$2Other$$aEfficacy
000186587 650_7 $$2Other$$aIDH-mutation
000186587 650_7 $$2Other$$aLow and intermediate grade glioma
000186587 650_7 $$2Other$$aProton radiotherapy
000186587 650_7 $$2Other$$aRadiation-induced contrast enhancement (RICE)
000186587 650_7 $$2Other$$aSafety
000186587 7001_ $$aLischalk, Jonathan W$$b1
000186587 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b2$$udkfz
000186587 7001_ $$aDeng, Maximilian$$b3
000186587 7001_ $$aMeixner, Eva$$b4
000186587 7001_ $$aKrämer, Anna$$b5
000186587 7001_ $$aHoegen, Philipp$$b6
000186587 7001_ $$aSandrini, Elisabetta$$b7
000186587 7001_ $$aRegnery, Sebastian$$b8
000186587 7001_ $$aHeld, Thomas$$b9
000186587 7001_ $$aHarrabi, Semi$$b10
000186587 7001_ $$aJungk, Christine$$b11
000186587 7001_ $$aHerfarth, Klaus$$b12
000186587 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b13$$udkfz
000186587 7001_ $$aKönig, Laila$$b14
000186587 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-022-04217-y$$n3$$p489-501$$tJournal of neuro-oncology$$v162$$x0167-594x$$y2023
000186587 909CO $$ooai:inrepo02.dkfz.de:186587$$pVDB
000186587 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000186587 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000186587 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000186587 9141_ $$y2023
000186587 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000186587 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000186587 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000186587 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000186587 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-20$$wger
000186587 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2022$$d2023-08-20
000186587 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-20
000186587 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-20
000186587 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-20
000186587 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-20
000186587 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-20
000186587 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-20
000186587 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000186587 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000186587 980__ $$ajournal
000186587 980__ $$aVDB
000186587 980__ $$aI:(DE-He78)E050-20160331
000186587 980__ $$aI:(DE-He78)HD01-20160331
000186587 980__ $$aUNRESTRICTED